ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 932,51
-0,66%
Dow Jones
38 021,82
0,31%
DAX
17 948,54
0,15%
Brent Oil
83,475
-0,08%
Bitcoin
58 458,90
0,38%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. AstraZeneca PLC (AZN)

  7. AstraZeneca PLC (AZN) Actualités

AZN

AstraZeneca (AZN)

AstraZeneca PLC
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:AZN
DateHeureSourceTitreSymboleSociété
01/11/202320h15AllPennyStocks.comBiotech Shares Soar After AstraZeneca Stake & Research CollaborationNYSE:AZNAstraZeneca PLC
28/06/202323h28Edgar (US Regulatory)Annual Report of Employee Stock Plans (11-k)NYSE:AZNAstraZeneca PLC
02/06/202318h13Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NYSE:AZNAstraZeneca PLC
13/03/202321h38Edgar (US Regulatory)Securities Registration (section 12(b)) (8-a12b)NYSE:AZNAstraZeneca PLC
02/03/202322h55Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(2) (424b2)NYSE:AZNAstraZeneca PLC
01/03/202312h27Edgar (US Regulatory)Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)NYSE:AZNAstraZeneca PLC
24/01/202319h59Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NYSE:AZNAstraZeneca PLC
11/11/202212h43TipRanksFDA Approves AstraZeneca’s (NASDAQ:AZN) Lung Cancer Combination TreatmentNYSE:AZNAstraZeneca PLC
10/11/202214h06TipRanksAstraZeneca (NASDAQ:AZN) Stock Rises on Upbeat Q3 Results, Guidance LiftNYSE:AZNAstraZeneca PLC
01/11/202210h08TipRanksAstraZeneca’s COVID-19 Vaccine Granted Full Approval in EUNYSE:AZNAstraZeneca PLC
16/09/202213h30TipRanksAstraZeneca (NASDAQ: AZN) Up on Positive Clinical Data and Evusheld ApprovalNYSE:AZNAstraZeneca PLC
08/07/202222h58Edgar (US Regulatory)Statement of Ownership (sc 13g)NYSE:AZNAstraZeneca PLC
05/07/202215h31TipRanksHere’s How AstraZeneca Is Gearing up against LymphomaNYSE:AZNAstraZeneca PLC
27/06/202218h26TipRanksAstraZeneca’s Enhertu Wins Approval in EU by CHMPNYSE:AZNAstraZeneca PLC
10/06/202222h11Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NYSE:AZNAstraZeneca PLC
06/06/202209h50TipRanksAstraZeneca Breast Cancer Drug Shows Positive ResultsNYSE:AZNAstraZeneca PLC
04/05/202214h41TipRanksAstraZeneca (AZN) Receives a Buy from SVB SecuritiesNYSE:AZNAstraZeneca PLC
30/04/202205h49TipRanksAstraZeneca (AZN) Receives a Buy from Leerink PartnersNYSE:AZNAstraZeneca PLC
21/04/202200h12Business WireEVUSHELD™  significantly protected against symptomatic COVID-19 for at least six months in PROVENT Phase III trial in high-risk populationsNYSE:AZNAstraZeneca PLC
19/04/202213h03TipRanksAstrazeneca, Amoy Diagnostics to Develop Diagnostics ProgramsNYSE:AZNAstraZeneca PLC
06/04/202213h00Business WireULTOMIRIS® (ravulizumab-cwvz) demonstrated sustained improvements in functional activities and quality of life in adults with generalized myasthenia gravis through 60 weeksNYSE:AZNAstraZeneca PLC
24/03/202212h00Business WireAstraZeneca Announces New Partnership with The National Fish and Wildlife Foundation to Plant One Million TreesNYSE:AZNAstraZeneca PLC
21/03/202212h00Business WireEVUSHELD™ long-acting antibody combination retains neutralizing activity against Omicron variants including BA.2 in new independent studiesNYSE:AZNAstraZeneca PLC
03/03/202208h56TipRanksAstraZeneca Acquires Neurimmune’s Heart Failure Drug CandidateNYSE:AZNAstraZeneca PLC
22/02/202223h43Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NYSE:AZNAstraZeneca PLC
22/02/202223h19Edgar (US Regulatory)Notice of Iran-related Disclosure Filed Pursuant to Section 13(r)(3) of the Exchange Act (irannotice)NYSE:AZNAstraZeneca PLC
21/02/202217h15Business WireENHERTU® (fam-trastuzumab deruxtecan-nxki) Significantly Improved Both Progression-Free and Overall Survival in DESTINY-Breast04 Trial in Patients with HER2-Low Metastatic Breast CancerNYSE:AZNAstraZeneca PLC
14/02/202223h00Business WireLYNPARZA® (olaparib) plus Abiraterone Reduced Risk of Disease Progression by 34% vs. Standard-of-Care in 1st-Line Metastatic Castration-Resistant Prostate CancerNYSE:AZNAstraZeneca PLC
04/02/202215h08Edgar (US Regulatory)Schedule 13gNYSE:AZNAstraZeneca PLC
25/01/202211h27TipRanksAstraZeneca Announces Orphan Drug Designation for Eplontersen in the U.S.NYSE:AZNAstraZeneca PLC
 Showing the most relevant articles for your search:NYSE:AZN

Dernières Valeurs Consultées

EU
BN
Danone
NYSE
NKE
Nike
NYSE
KO
Coca Cola
NASDAQ
AAPL
Apple
EU
ORA
Orange
NASDAQ
NVDA
NVIDIA
EU
PX1
CAC 40
COIN
BTCUSD
Bitcoin
EU
VIV
Vivendi
EU
ACA
Credit Agricole
EU
MC
Lvmh Moet Hennessy Louis...
EU
ML
Michelin
EU
GLE
Societe Generale
EU
HO
Thales
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés